Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

A 12-week randomized clinical trial investigating the potential for sucralose to affect glucose homeostasis.

Grotz VL, Pi-Sunyer X, Porte D Jr, Roberts A, Richard Trout J.

Regul Toxicol Pharmacol. 2017 Aug;88:22-33. doi: 10.1016/j.yrtph.2017.05.011. Epub 2017 May 11.

2.

Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics.

Matschinsky FM, Porte D.

F1000 Med Rep. 2010 Jun 16;2. pii: 43. doi: 10.3410/M2-43.

3.

The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes.

Triplitt C, McGill JB, Porte D Jr, Conner CS.

J Manag Care Pharm. 2007 Dec;13(9 Suppl C):S2-16; quiz S17. Review.

PMID:
18062735
4.

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.

Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association.

Circulation. 2007 Jan 2;115(1):114-26. Epub 2006 Dec 27.

PMID:
17192512
5.

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.

Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association.

Diabetes Care. 2007 Jan;30(1):162-72. Review.

PMID:
17192355
6.
7.

Diabetes, obesity, and the brain.

Schwartz MW, Porte D Jr.

Science. 2005 Jan 21;307(5708):375-9.

PMID:
15662002
8.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R.

Diabetes Care. 2004 Jan;27(1):256-63. Review. No abstract available.

PMID:
14693998
9.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association.

Circulation. 2003 Dec 9;108(23):2941-8. Review. No abstract available.

PMID:
14662691
10.

Leptin and insulin action in the central nervous system.

Porte D Jr, Baskin DG, Schwartz MW.

Nutr Rev. 2002 Oct;60(10 Pt 2):S20-9; discussion S68-84, 85-7. Review.

PMID:
12403080
11.

Expression of collagenase-3 (MMP-13) in c-fos-induced osteosarcomas and chondrosarcomas is restricted to a subset of cells of the osteo-/chondrogenic lineage.

Tuckermann JP, Vallon R, Gack S, Grigoriadis AE, Porte D, Lutz A, Wagner EF, Schmidt J, Angel P.

Differentiation. 2001 Dec;69(1):49-57.

PMID:
11776394
14.

beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms.

Porte D Jr, Kahn SE.

Diabetes. 2001 Feb;50 Suppl 1:S160-3. Review.

15.

Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity.

Kahn SE, Prigeon RL, Schwartz RS, Fujimoto WY, Knopp RH, Brunzell JD, Porte D Jr.

J Nutr. 2001 Feb;131(2):354S-60S. Review.

PMID:
11160560
16.

Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction.

Porte D Jr.

Ann N Y Acad Sci. 1999 Nov 18;892:73-83. Review.

PMID:
10842653
17.

Central nervous system control of food intake.

Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG.

Nature. 2000 Apr 6;404(6778):661-71. Review.

PMID:
10766253
18.

Comments on the relation among GAD-65, IA-2 antibodies and body adiposity.

Porte D Jr, Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW.

Diabetologia. 2000 Jan;43(1):134. No abstract available.

PMID:
10672457
19.

Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight.

Baskin DG, Figlewicz Lattemann D, Seeley RJ, Woods SC, Porte D Jr, Schwartz MW.

Brain Res. 1999 Nov 27;848(1-2):114-23. Review.

PMID:
10612703
20.

Reduced beta-cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding.

Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Porte D Jr, Schwartz MW.

Am J Physiol. 1999 Oct;277(4):E659-67. doi: 10.1152/ajpendo.1999.277.4.E659.

PMID:
10516125
21.

The JIM interview. Daniel Porte, Jr, MD.

Porte D Jr.

J Investig Med. 1999 Mar;47(3):101-5. No abstract available.

PMID:
10198564
22.

Leptin receptor long-form splice-variant protein expression in neuron cell bodies of the brain and co-localization with neuropeptide Y mRNA in the arcuate nucleus.

Baskin DG, Schwartz MW, Seeley RJ, Woods SC, Porte D Jr, Breininger JF, Jonak Z, Schaefer J, Krouse M, Burghardt C, Campfield LA, Burn P, Kochan JP.

J Histochem Cytochem. 1999 Mar;47(3):353-62.

PMID:
10026237
23.

Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone.

Porte D, Tuckermann J, Becker M, Baumann B, Teurich S, Higgins T, Owen MJ, Schorpp-Kistner M, Angel P.

Oncogene. 1999 Jan 21;18(3):667-78.

24.

NPY and food intake: discrepancies in the model.

Woods SC, Figlewicz DP, Madden L, Porte D Jr, Sipols AJ, Seeley RJ.

Regul Pept. 1998 Sep 25;75-76:403-8. Review.

PMID:
9802436
25.

Obesity, diabetes and the central nervous system.

Porte D Jr, Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW.

Diabetologia. 1998 Aug;41(8):863-81. Review. No abstract available.

PMID:
9726588
26.

Signals that regulate food intake and energy homeostasis.

Woods SC, Seeley RJ, Porte D Jr, Schwartz MW.

Science. 1998 May 29;280(5368):1378-83. Review.

PMID:
9603721
27.
28.

A new LexA-based genetic system for monitoring and analyzing protein heterodimerization in Escherichia coli.

Dmitrova M, Younès-Cauet G, Oertel-Buchheit P, Porte D, Schnarr M, Granger-Schnarr M.

Mol Gen Genet. 1998 Jan;257(2):205-12.

PMID:
9491079
29.
30.

Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype.

Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr.

Neurology. 1998 Jan;50(1):164-8.

PMID:
9443474
31.

Evidence that plasma leptin and insulin levels are associated with body adiposity via different mechanisms.

Schwartz MW, Prigeon RL, Kahn SE, Nicolson M, Moore J, Morawiecki A, Boyko EJ, Porte D Jr.

Diabetes Care. 1997 Sep;20(9):1476-81.

PMID:
9283801
32.

DNA binding and transactivation properties of Fos variants with homodimerization capacity.

Porte D, Oertel-Buchheit P, John M, Granger-Schnarr M, Schnarr M.

Nucleic Acids Res. 1997 Aug 1;25(15):3026-33.

34.

Intraventricular neuropeptide Y does not stimulate food intake in the baboon.

Sipols AJ, Figlewicz DP, Seeley RJ, Chavez M, Woods SC, Porte D Jr.

Physiol Behav. 1996 Sep;60(3):717-9.

PMID:
8873242
35.
36.

Diabetes complications: why is glucose potentially toxic?

Porte D Jr, Schwartz MW.

Science. 1996 May 3;272(5262):699-700. Review. No abstract available. Erratum in: Science 1996 Jun 28;272(5270):1861.

PMID:
8614830
37.

Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans.

Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D Jr.

Nat Med. 1996 May;2(5):589-93.

PMID:
8616722
38.

Endocrine regulation of food intake and body weight.

Figlewicz DP, Schwartz MW, Seeley RJ, Chavez M, Baskin DG, Woods SC, Porte D Jr.

J Lab Clin Med. 1996 Apr;127(4):328-32. Review. No abstract available.

PMID:
8656034
39.

Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice.

Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte D Jr, Woods SC, Seeley RJ, Weigle DS.

Diabetes. 1996 Apr;45(4):531-5.

PMID:
8603777
40.
41.

The effect of epinephrine on immunoreactive insulin levels in man: 1965.

Porte D Jr, Graber AL, Kuzuya T, Williams RH.

Nutrition. 1996 Mar;12(3):225-6; discussion 224, 226. No abstract available.

PMID:
8798235
42.

Report of the American Diabetes Association's Task Force on standardization of the insulin assay.

Robbins DC, Andersen L, Bowsher R, Chance R, Dinesen B, Frank B, Gingerich R, Goldstein D, Widemeyer HM, Haffner S, Hales CN, Jarett L, Polonsky K, Porte D, Skyler J, Webb G, Gallagher K.

Diabetes. 1996 Feb;45(2):242-56.

PMID:
8549870
44.

Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans.

Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte D Jr, Robertson RP.

J Clin Invest. 1996 Jan 15;97(2):455-60.

45.

The evaluation of insulin as a metabolic signal influencing behavior via the brain.

Woods SC, Chavez M, Park CR, Riedy C, Kaiyala K, Richardson RD, Figlewicz DP, Schwartz MW, Porte D Jr, Seeley RJ.

Neurosci Biobehav Rev. 1996;20(1):139-44. Review.

PMID:
8622820
46.

Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs.

Baura GD, Foster DM, Kaiyala K, Porte D Jr, Kahn SE, Schwartz MW.

Diabetes. 1996 Jan;45(1):86-90.

PMID:
8522065
47.

Changes in insulin sensitivity, glucose effectiveness, and B-cell function in regularly exercising subjects.

Prigeon RL, Kahn SE, Porte D Jr.

Metabolism. 1995 Oct;44(10):1259-63.

PMID:
7476281
48.

Fos leucine zipper variants with increased association capacity.

Porte D, Oertel-Buchheit P, Granger-Schnarr M, Schnarr M.

J Biol Chem. 1995 Sep 29;270(39):22721-30.

49.

The key role of islet dysfunction in type II diabetes mellitus.

Porte D Jr, Kahn SE.

Clin Invest Med. 1995 Aug;18(4):247-54. Review.

PMID:
8549009
50.

Intraventricular insulin enhances the meal-suppressive efficacy of intraventricular cholecystokinin octapeptide in the baboon.

Figlewicz DP, Sipols AJ, Seeley RJ, Chavez M, Woods SC, Porte D Jr.

Behav Neurosci. 1995 Jun;109(3):567-9.

PMID:
7662167

Supplemental Content

Support Center